{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:58:32Z","timestamp":1753441112607},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,19]]},"DOI":"10.7759\/cureus.27017","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T16:12:08Z","timestamp":1658247128000},"source":"Crossref","is-referenced-by-count":1,"title":["Granulocyte Colony-Stimulating Factor Utilization and Prescribing Patterns in Cancer Patients: A Single Institution Experience of a Saudi Cancer Center"],"prefix":"10.7759","author":[{"given":"Mohammad J","family":"Alyamani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haya","family":"AlSalloum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghada","family":"Elgohary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Alsaleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Abd El Warith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nashwa","family":"Abd El-Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer NM","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006, 106:2258-66. 10.1002\/cncr.21847","journal-title":"Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2012.000662","article-title":"Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic","volume":"9","author":"Waters GE","year":"2012","unstructured":"Waters GE, Corrigan P, Gatesman M, Smith TJ. Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic. J Oncol Pract. 2012, 9:203-6. 10.1200\/JOP.2012.000662","journal-title":"J Oncol Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262001-00001","article-title":"Colony-stimulating factors for the management of neutropenia in cancer patients","volume":"62 Suppl 1","author":"Dale DC","year":"2002","unstructured":"Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs. 2002, 62 Suppl 1:1-15. 10.2165\/00003495-200262001-00001","journal-title":"Drugs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"Klastersky J","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016, 27:v111-8. 10.1093\/annonc\/mdw325","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.002","article-title":"Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices","volume":"21","author":"Lyman GH","year":"2003","unstructured":"Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003, 21:4524-31. 10.1200\/JCO.2003.05.002","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/107327489600300605","article-title":"Use of G-CSF to sustain dose intensity in breast cancer patients receiving adjuvant chemotherapy: a pilot study","volume":"3","author":"Webster J","year":"1996","unstructured":"Webster J, Lyman GH. Use of G-CSF to sustain dose intensity in breast cancer patients receiving adjuvant chemotherapy: a pilot study. Cancer Control. 1996, 3:519-23. 10.1177\/107327489600300605","journal-title":"Cancer Control"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2165\/11590130-000000000-00000","article-title":"Pharmacoeconomics of the myeloid growth factors: a critical and systematic review","volume":"30","author":"Hirsch BR","year":"2012","unstructured":"Hirsch BR, Lyman GH. Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. Pharmacoeconomics. 2012, 30:497-511. 10.2165\/11590130-000000000-00000","journal-title":"Pharmacoeconomics"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2454-9","article-title":"Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy","volume":"138","author":"Chia VM","year":"2013","unstructured":"Chia VM, Page JH, Rodriguez R, et al.. Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy. Breast Cancer Res Treat. 2013, 138:621-31. 10.1007\/s10549-013-2454-9","journal-title":"Breast Cancer Res Treat"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2011.312","article-title":"Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study","volume":"2","author":"SC MB","year":"2011","unstructured":"SC MB, PA C, DE RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med. 2011, 2:859-66. 10.3892\/etm.2011.312","journal-title":"Exp Ther Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky053","article-title":"Development and validation of a risk score for febrile neutropenia after chemotherapy in patients with cancer: the FENCE score","volume":"2","author":"Aagaard T","year":"2018","unstructured":"Aagaard T, Roen A, Reekie J, et al.. Development and validation of a risk score for febrile neutropenia after chemotherapy in patients with cancer: the FENCE score. JNCI Cancer Spectr. 2018, 2:pky053. 10.1093\/jncics\/pky053","journal-title":"JNCI Cancer Spectr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.645","article-title":"Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials","volume":"23","author":"Clark OA","year":"2005","unstructured":"Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005, 23:4198-214. 10.1200\/JCO.2005.05.645","journal-title":"J Clin Oncol"},{"key":"ref12","article-title":"Efficacy of granulocyte colony stimulating factor as a secondary prophylaxis along with full-dose chemotherapy following a prior cycle of febrile neutropenia","volume":"4","author":"Gupta S","year":"2010","unstructured":"Gupta S, Singh PK, Bhatt ML, Pant MC, Gupta R, Negi MP. Efficacy of granulocyte colony stimulating factor as a secondary prophylaxis along with full-dose chemotherapy following a prior cycle of febrile neutropenia. Biosci Trends. 2010, 4:273-8.","journal-title":"Biosci Trends"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt226","article-title":"The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Lyman GH","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E, et al.. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013, 24:2475-84. 10.1093\/annonc\/mdt226","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct1210890","article-title":"Colony-stimulating factors for febrile neutropenia during cancer therapy","volume":"368","author":"Bennett CL","year":"2013","unstructured":"Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013, 368:1131-9. 10.1056\/NEJMct1210890","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer NM","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007, 25:3158-67. 10.1200\/JCO.2006.08.8823","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-6-200709180-00010","article-title":"Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection","volume":"147","author":"Sung L","year":"2007","unstructured":"Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007, 147:400-11. 10.7326\/0003-4819-147-6-200709180-00010","journal-title":"Ann Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500861","article-title":"G-CSF and GM-CSF in neutropenia","volume":"195","author":"Mehta HM","year":"2015","unstructured":"Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in neutropenia. J Immunol. 2015, 195:1341-9. 10.4049\/jimmunol.1500861","journal-title":"J Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro MS","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, et al.. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011, 47:8-32. 10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america","volume":"52","author":"Freifeld AG","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, et al.. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011, 52:e56-93. 10.1093\/cid\/cir073","journal-title":"Clin Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith TJ","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH, et al.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006, 24:3187-205. 10.1200\/JCO.2006.06.4451","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51982-4","article-title":"Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: a systematic review and Bayesian network meta-analysis","volume":"9","author":"Wang Y","year":"2019","unstructured":"Wang Y, Chen L, Liu F, Zhao N, Xu L, Fu B, Li Y. Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: a systematic review and Bayesian network meta-analysis. Sci Rep. 2019, 9:15374. 10.1038\/s41598-019-51982-4","journal-title":"Sci Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu203","article-title":"History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis","volume":"25","author":"Chao C","year":"2014","unstructured":"Chao C, Page JH, Yang SJ, Rodriguez R, Huynh J, Chia VM. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann Oncol. 2014, 25:1821-9. 10.1093\/annonc\/mdu203","journal-title":"Ann Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2471\/blt.08.050955","article-title":"The Declaration of Helsinki and public health","volume":"86","author":"Williams JR","year":"2008","unstructured":"Williams JR. The Declaration of Helsinki and public health. Bull World Health Organ. 2008, 86:650-2. 10.2471\/blt.08.050955","journal-title":"Bull World Health Organ"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605269","article-title":"Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors","volume":"101 Suppl 1","author":"Kelly S","year":"2009","unstructured":"Kelly S, Wheatley D. Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Br J Cancer. 2009, 101 Suppl 1:S6-10. 10.1038\/sj.bjc.6605269","journal-title":"Br J Cancer"},{"key":"ref25","article-title":"Prophylactic use of granulocyte colony stimulating factor (G-CSF) in febrile neutropenia- a single institutional study","volume":"8","author":"Wani SQ","year":"2019","unstructured":"Wani SQ, Khan T, Lone MM. Prophylactic use of granulocyte colony stimulating factor (G-CSF) in febrile neutropenia- a single institutional study. World J Surg Med Radiat Oncol. 2019, 8:","journal-title":"World J Surg Med Radiat Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.782034","article-title":"A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia","volume":"16","author":"Dulisse B","year":"2013","unstructured":"Dulisse B, Li X, Gayle JA, et al.. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ. 2013, 16:720-35. 10.3111\/13696998.2013.782034","journal-title":"J Med Econ"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3692-x","article-title":"Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population","volume":"25","author":"Kawatkar AA","year":"2017","unstructured":"Kawatkar AA, Farias AJ, Chao C, Chen W, Barron R, Vogl FD, Chandler DB. Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population. Support Care Cancer. 2017, 25:2787-95. 10.1007\/s00520-017-3692-x","journal-title":"Support Care Cancer"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.019588","article-title":"Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012","volume":"13","author":"Tai E","year":"2017","unstructured":"Tai E, Guy GP, Dunbar A, Richardson LC. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. 2017, 13:e552-61. 10.1200\/JOP.2016.019588","journal-title":"J Oncol Pract"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0014","article-title":"Management of chemotherapy-induced neutropenia: measuring quality, cost, and value","volume":"13","author":"Dinan MA","year":"2015","unstructured":"Dinan MA, Hirsch BR, Lyman GH. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. J Natl Compr Canc Netw. 2015, 13:e1-7. 10.6004\/jnccn.2015.0014","journal-title":"J Natl Compr Canc Netw"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00242.x","article-title":"Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy","volume":"11","author":"Eldar-Lissai A","year":"2008","unstructured":"Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health. 2008, 11:172-9. 10.1111\/j.1524-4733.2007.00242.x","journal-title":"Value Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/93571-granulocyte-colony-stimulating-factor-utilization-and-prescribing-patterns-in-cancer-patients-a-single-institution-experience-of-a-saudi-cancer-center","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:45:43Z","timestamp":1707507943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/93571-granulocyte-colony-stimulating-factor-utilization-and-prescribing-patterns-in-cancer-patients-a-single-institution-experience-of-a-saudi-cancer-center"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.27017","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,19]]}}}